Tamiflu cleared for wider prophylactic use in Japan
This article was originally published in Scrip
Tamiflu (oseltamivir) has been approved in Japan for broader use in the prophylaxis of A and B type influenza in adults, children and infants, although the neuraminidase inhibitor will not be eligible for reimbursement under the country's national health insurance system in this setting.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.